Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage Cancer

Inclusion Criteria

• •1. Age ≥18 years at the time of study entry.
• •2. Patient with histologically documented early stage solid malignant tumor (NSCLC, head and neck cancer, melanoma (except uveal melanoma), bladder cancer or any other early stage solid tumor when I-O agent is expected to be efficient in a neo-adjuvant setting (whether in standard of care or within a clinical trial).
• •3. Patient for whom a neo-adjuvant treatment with immune checkpoint blockade including, but not limited to, anti-PD-1, anti-PD-L1 and anti-CTLA-4 mAb alone or in combination with chemotherapy or other therapies has been decided.
• •4. Availability of an archived tumor specimen (block FFPE) sampled prior to the start of the treatment.
• •5. Treatment with ICB not yet started.
• •6. ECOG Performance status 0-2.
• •7. Patient able to participate and willing to give informed consent prior to performance of any study-related procedures.
• •8. Patient affiliated to a Social Health Insurance in France.